A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Category Systematic review
JournalHealth technology assessment (Winchester, England)
Year 2006
Links Pubmed, DOI

This article is included in 1 Structured summary of systematic reviews 30 Structured summaries of systematic reviews (1 reference) 3 Broad syntheses 30 Broad syntheses (3 references)

This article includes 36 Primary studies 30 Primary studies (36 references)

This article is part of the following publication threads:
This article is part of the following matrixes of evidence:
Loading references information

OBJECTIVES:

This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults.

DATA SOURCES:

Electronic databases were searched up to February 2005.

REVIEW METHODS:

Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis.

RESULTS:

Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against methotrexate. For patients with short disease duration (






Epistemonikos ID.: fa341b1071144639f2b733e59cd0c2cb35f61029


First added on: Sep 01, 2014